


Pharmaceuticals an Open Access Journal by MDPI

Impact Factor 4.3 CiteScore 6.1 Indexed in PubMed

Section Biopharmaceuticals



mdpi.com/ journal/ pharmaceuticals



Section Information

This section is dedicated to research on the therapeutic, diagnostic, prognostic and immunoprophylactic developments of important biological macromolecules built from amino acids, sugars, nucleic acids, comprising small basic units of which they are composed, and mimetics produced by chemical synthesis. Contributions focusing on biopharmaceutical applications of more complex entities, such as phages, viruses, exosomes and stem cells, among others, are also welcome. Also reports on structure and molecular interactions determinant for biopharmaceuticals bioactivity or pharmaceutical applications, e.g. by computational and NMR studies are also accepted.

Keywords

- Peptides
- Proteins
- RNA
- DNA
- Nucleic Acids
- Aptamers
- Carbohydrates
- Glycans
- Polysaccharides
- Macromolecules

Section Editor-in-Chief

Dr. Alfredo Berzal-Herranz

Editorial Office

pharmaceuticals@mdpi.com

MDPI Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 mdpi.com

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

2023 Impact Factor: 4.3

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Pharmaceutical Science)

Discounts on Article Processing Charges (APC)

If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures or colors

Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases

Rapid Publication

A first decision is provided to authors approximately 12.8 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2024)